209 related articles for article (PubMed ID: 27607585)
1. Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients.
Banfield E; Brown AL; Peckham EC; Rednam SP; Murray J; Okcu MF; Mitchell LE; Chintagumpala MM; Lau CC; Scheurer ME; Lupo PJ
Cancer Epidemiol; 2016 Oct; 44():161-166. PubMed ID: 27607585
[TBL] [Abstract][Full Text] [Related]
2. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
4. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
6. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
[TBL] [Abstract][Full Text] [Related]
7. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract][Full Text] [Related]
8. Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma.
Bowers DC; Gargan L; Weprin BE; Mulne AF; Elterman RD; Munoz L; Giller CA; Winick NJ
J Neurosurg; 2007 Jul; 107(1 Suppl):5-10. PubMed ID: 17644914
[TBL] [Abstract][Full Text] [Related]
9. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.
Rednam S; Scheurer ME; Adesina A; Lau CC; Okcu MF
Pediatr Blood Cancer; 2013 Apr; 60(4):593-8. PubMed ID: 23065688
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
11. HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and Increases EPAS1 and ATG16L1 Methylation.
Cruzeiro GAV; Dos Reis MB; Silveira VS; Lira RCP; Carlotti CG; Neder L; Oliveira RS; Yunes JA; Brandalise SR; Aguiar S; Eterovic AK; Tone LG; Scrideli CA; Valera ET
Curr Cancer Drug Targets; 2018; 18(3):287-294. PubMed ID: 28302031
[TBL] [Abstract][Full Text] [Related]
12. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract][Full Text] [Related]
13. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
[TBL] [Abstract][Full Text] [Related]
14. A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma.
Michaelsen GL; da Silva LDRE; de Lima DS; Jaeger MDC; Brunetto AT; Dalmolin RJS; Sinigaglia M
J Mol Neurosci; 2024 Apr; 74(2):47. PubMed ID: 38662144
[TBL] [Abstract][Full Text] [Related]
15. [Risk stratification in medulloblastoma: screening for molecular markers].
Ebinger M; Senf L; Scheurlen W
Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma.
Arroyo VM; Lupo PJ; Scheurer ME; Rednam SP; Murray J; Okcu MF; Chintagumpala MM; Brown AL
Cancer Epidemiol; 2019 Apr; 59():71-74. PubMed ID: 30703618
[TBL] [Abstract][Full Text] [Related]
17. C-MYC expression in medulloblastoma and its prognostic value.
Herms J; Neidt I; Lüscher B; Sommer A; Schürmann P; Schröder T; Bergmann M; Wilken B; Probst-Cousin S; Hernáiz-Driever P; Behnke J; Hanefeld F; Pietsch T; Kretzschmar HA
Int J Cancer; 2000 Sep; 89(5):395-402. PubMed ID: 11008200
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility.
Frühwald MC; O'Dorisio MS; Dai Z; Tanner SM; Balster DA; Gao X; Wright FA; Plass C
Oncogene; 2001 Aug; 20(36):5033-42. PubMed ID: 11526488
[TBL] [Abstract][Full Text] [Related]
19. DNA content and other prognostic features in childhood medulloblastoma. Proposal of a scoring system.
Schofield DE; Yunis EJ; Geyer JR; Albright AL; Berger MS; Taylor SR
Cancer; 1992 Mar; 69(5):1307-14. PubMed ID: 1739930
[TBL] [Abstract][Full Text] [Related]
20. Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2.
Anderton JA; Lindsey JC; Lusher ME; Gilbertson RJ; Bailey S; Ellison DW; Clifford SC
Neuro Oncol; 2008 Dec; 10(6):981-94. PubMed ID: 18664619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
